Clinical Trials | A Randomized Phase II trial for those with EGFR-Mutant, MET-Amplified IV or Recurrent Non-Small Cell Lung Cancer
A Randomized Phase II Study of Capmatinib plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
The UVA Cancer Center has a clinical trial for adults over the age of 18 and who have EGFR-Mutant, MET-Amplified IV or Recurrent Non-Small Cell Lung Cancer. This study is part of a larger research study whose purpose is to test the efficacy of capmatinib and osimertinib with or without the addition of ramucirumab. The results of genetic testing on your cancer will determine which group you are assigned to. Participants in this study will take experimental medicine, undergo imaging (i.e., x-rays, MRIs, CTs), have blood draws, and other sample collections. This study has 4 cycles where 1 cycle is 28 days long. Participants will have clinic visits before starting each cycle. Study-related (insert exams, tests and experimental medication) provided at no cost.